Litcius/Paper detail

Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation

Pamina Kazman, M.-T. Vielberg, María Daniela Pulido Cendales, Lioba Hunziger, Benedikt Weber, Ute Hegenbart, Martin Zacharias, Rolf Köhler, Stefan Schönland, M. Groll, Johannes Büchner

2020eLife57 citationsDOIOpen Access PDF

Abstract

In systemic light chain amyloidosis, an overexpressed antibody light chain (LC) forms fibrils which deposit in organs and cause their failure. While it is well-established that mutations in the LC’s VL domain are important prerequisites, the mechanisms which render a patient LC amyloidogenic are ill-defined. In this study, we performed an in-depth analysis of the factors and mutations responsible for the pathogenic transformation of a patient-derived λ LC, by recombinantly expressing variants in E. coli. We show that proteolytic cleavage of the patient LC resulting in an isolated VL domain is essential for fibril formation. Out of 11 mutations in the patient VL, only one, a leucine to valine mutation, is responsible for fibril formation. It disrupts a hydrophobic network rendering the C-terminal segment of VL more dynamic and decreasing domain stability. Thus, the combination of proteolytic cleavage and the destabilizing mutation trigger conformational changes that turn the LC pathogenic.

Topics & Concepts

Point mutationImmunoglobulin light chainMutationAmyloid (mycology)AntibodyChemistryChain (unit)GeneticsMolecular biologyBiologyBiochemistryPhysicsGeneAstronomyInorganic chemistryAmyloidosis: Diagnosis, Treatment, OutcomesChronic Lymphocytic Leukemia ResearchProtein Kinase Regulation and GTPase Signaling
Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation | Litcius